pH-Responsive Fusion Peptide for Intracellular Prion Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development methods are ineffective for treating amyloid-associated diseases due to the absence of distinct recognition sites or binding pockets in amyloid proteins, and existing inhibitors are only effective for single molecular species, limiting their applicability to various amyloid aggregates or prions.
Innovation Solution
A pH-responsive fusion peptide containing a cell-penetrating peptide with 2-15 arginine residues and a β-sheet-forming segment, which self-assembles into a vesicular nanostructure under acidic conditions within cells, specifically inhibiting protein misfolding and aggregation in endosomes and lysosomes, thereby preventing the conversion of normal prion proteins to infectious forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a fusion peptide is designed to inhibit protein misfolding and aggregation, then anti-prion activity is improved, but cytotoxicity increases
Solution Approach 1:
The fusion peptide is designed with distinct functional domains: a cell-penetrating peptide segment (2-15 arginine residues) for cellular uptake and a β-sheet-forming segment for anti-prion activity. Each segment has optimized local properties - the arginine-rich region provides positive charge for membrane interaction while the β-sheet region provides structural stability and anti-aggregation activity, reducing overall cytotoxicity while maintaining efficacy
Solution Approach 2:
The fusion peptide exploits pH parameter changes between extracellular environment (pH 7.4) and intracellular endosomes/lysosomes (pH 4.5-5.5). The peptide remains stable and inactive at neutral pH but undergoes conformational change and self-assembly into active nanostructures under acidic conditions, providing selective anti-prion activity inside cells while minimizing extracellular cytotoxicity
2Measurement precision
If existing inhibitors are used to treat amyloid-associated diseases, then single molecular species are targeted, but applicability to various amyloid aggregates or prions is limited
Solution Approach 1:
The fusion peptide is designed with universal applicability through its β-sheet-forming segment that can interact with multiple types of amyloid aggregates and misfolded proteins. The peptide's ability to form β-sheet structures allows it to bind to various amyloid fibrils through hydrophobic and electrostatic interactions, making it effective against different molecular species including Alzheimer's amyloid-beta, Parkinson's alpha-synuclein, and prion proteins
Solution Approach 2:
The fusion peptide combines two distinct functional segments - a cell-penetrating peptide (oligoarginine) and a β-sheet-forming segment - into a single molecule. This composite structure integrates cellular uptake capability with broad-spectrum anti-amyloid activity, creating a multi-functional inhibitor that can target various protein aggregation diseases
3Ease of manufacture
If drug development methods are applied to amyloid-associated diseases, then treatment approaches are attempted, but effectiveness is reduced due to absence of distinct recognition sites or binding pockets in amyloid proteins
Solution Approach 1:
Instead of relying on traditional lock-and-key molecular recognition mechanisms that require specific binding pockets, the fusion peptide uses physical-chemical interactions including hydrophobic effects, electrostatic interactions, and β-sheet stacking. This substitution of recognition mechanism allows the peptide to bind to amyloid surfaces without requiring distinct molecular recognition sites, overcoming a major limitation in amyloid drug development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion peptide exhibits low cytotoxicity and high anti-prion activity specifically within cells, effectively preventing protein misfolding and aggregation, and can treat a wide range of diseases associated with abnormal protein aggregation, including Alzheimer's and prion diseases, without causing side effects outside the cell.
Implementation Method 1
The fusion peptide may form a nanostructure through self-assembly between fusion peptides via hydrophobic interaction and electrostatic binding of the β-sheet-forming segment under an acidic condition (pH 2-5.5)
Implementation Method 2
The fusion peptide may form a nanostructure through self-assembly between fusion peptides via hydrophobic interaction and electrostatic binding of the β-sheet-forming segment under an acidic condition (pH 2-5.5)
Implementation Method 3
upon uptake into a cell by endocytosis
Data Source
AI summary
A pH-responsive fusion peptide according to the present disclosure, containing a cell-penetrating peptide exhibiting a positive charge, which contains 2-15 arginine residues, and a β-sheet-forming segment, experiences structural change depending on pH change. Due to the structural change, the anti-prion activity and cytotoxicity of the fusion peptide can be controlled as desired.